Trophos
Latest round
- Series C
Last raised
- Sep 2007
Total raised
- $19M
Investors
- 4
About Trophos
Founded in 1999 in Marseille, France, Trophos specializes in biopharmaceuticals targeting neurodegenerative diseases.000 mn, marking a significant shift in the company's trajectory after a previous acquisition option by Actelion in 2010 was not exercised. The company has engaged in three total deals, with the most recent occurring on January 16, 2015.Trophos focuses on developing innovative therapies for neurodegenerative conditions, including a significant emphasis on treatments for ALS.28 mn. Following the acquisition deal in January 2015, the company aims to enhance its R&D capabilities and expand its presence in international markets to facilitate the launch of its product pipeline focused on ALS and similar disorders.
Who invested in Trophos
4 investors across 2 rounds
See all investors in Trophos
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Trophos
Who invested in Trophos?
Trophos has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Trophos raised?
Trophos has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Trophos last raise money?
Trophos's most recent round on record is a Series C, in Sep 2007.
What does Trophos do?
Founded in 1999 in Marseille, France, Trophos specializes in biopharmaceuticals targeting neurodegenerative diseases.
Where is Trophos headquartered?
Trophos is headquartered in Marseille, France.
Which VCs invest in companies like Trophos?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Trophos's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Trophos? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.